Literature DB >> 17967859

A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis.

Delin Zhu1, Jeannette N Williams, Jason Rice, Freda K Stevenson, John E Heckels, Myron Christodoulides.   

Abstract

An experimental DNA plasmid vaccine was developed based on a well-characterized and protective peptide epitope derived from a bacterial porin protein. For this study, we used the P1.16b serosubtype epitope, located in variable region (VR)2 in loop 4 of the PorA outer membrane (OM) porin from Neisseria meningitidis serogroup B strain MC58. A plasmid that encoded the entire loop (pPorAloop4) was prepared, as well as a fusion plasmid that encoded the loop in tandem with the fragment C (FrC) immunostimulatory sequence from tetanus toxin (pPorAloop4-FrC). The constructs were used for intramuscular immunization without exogenous adjuvant. Murine antisera raised to the pPorAloop4-FrC DNA fusion plasmid reacted significantly with OMs in enzyme-linked immunosorbent assay and with whole bacteria by immunofluorescence, whereas antisera raised to the pPorAloop4 DNA plasmid and to control plasmid showed little or no reactivity. Significantly, only the pPorALoop4-FrC plasmid induced bactericidal antibodies, demonstrating that the intrinsic immunostimulatory sequence was essential for inducing a protective immune response. The antibodies raised to the P1.16b pPorALoop4-FrC plasmid were serosubtype specific, showing no significant immunofluorescence reactivity or bactericidal activity against other PorA variants. These data provide proof of principle for a DNA fusion plasmid strategy as a novel approach to preparing vaccines based on defined, protective epitopes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967859      PMCID: PMC2223639          DOI: 10.1128/IAI.00943-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

Authors:  T P Le; K M Coonan; R C Hedstrom; Y Charoenvit; M Sedegah; J E Epstein; S Kumar; R Wang; D L Doolan; J D Maguire; S E Parker; P Hobart; J Norman; S L Hoffman
Journal:  Vaccine       Date:  2000-03-17       Impact factor: 3.641

2.  Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis.

Authors:  Holly E Humphries; Jeannette N Williams; Ramona Blackstone; Keith A Jolley; Ho M Yuen; Myron Christodoulides; John E Heckels
Journal:  Vaccine       Date:  2005-08-02       Impact factor: 3.641

Review 3.  Update on viral vaccines for fish.

Authors:  E Biering; S Villoing; I Sommerset; K E Christie
Journal:  Dev Biol (Basel)       Date:  2005

4.  DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.

Authors:  C A King; M B Spellerberg; D Zhu; J Rice; S S Sahota; A R Thompsett; T J Hamblin; J Radl; F K Stevenson
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

5.  Increased DNA vaccine delivery and immunogenicity by electroporation in vivo.

Authors:  G Widera; M Austin; D Rabussay; C Goldbeck; S W Barnett; M Chen; L Leung; G R Otten; K Thudium; M J Selby; J B Ulmer
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

6.  Turkeys are protected from infection with Chlamydia psittaci by plasmid DNA vaccination against the major outer membrane protein.

Authors:  D Vanrompay; E Cox; G Volckaert; B Goddeeris
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

7.  Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci.

Authors:  Myron Christodoulides; Joy L Brooks; Elizabeth Rattue; John E Heckels
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

8.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

9.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

Authors:  R R MacGregor; J D Boyer; K E Ugen; K E Lacy; S J Gluckman; M L Bagarazzi; M A Chattergoon; Y Baine; T J Higgins; R B Ciccarelli; L R Coney; R S Ginsberg; D B Weiner
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci.

Authors:  Concetta Beninati; Angelina Midiri; Giuseppe Mancuso; Carmelo Biondo; Milena Arigò; Elisabetta Gerace; Salvatore Papasergi; Maria Gambuzza; Mauro Boretti; Walter Magliani; Stefania Conti; Luciano Polonelli; Giuseppe Teti
Journal:  J Exp Med       Date:  2006-01-03       Impact factor: 14.307

View more
  4 in total

Review 1.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

2.  Evaluation of a novel chimeric B cell epitope-based vaccine against mastitis induced by either Streptococcus agalactiae or Staphylococcus aureus in mice.

Authors:  Haiyang Xu; Changmin Hu; Rui Gong; Yingyu Chen; Ningning Ren; Ganwen Xiao; Qian Xie; Minmin Zhang; Qin Liu; Aizhen Guo; Huanchun Chen
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

3.  Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Authors:  Abel E Vasquez; Ricardo A Manzo; Daniel A Soto; Magaly J Barrientos; Aurora E Maldonado; Macarena Mosqueira; Anastasia Avila; Jorge Touma; Elsa Bruce; Paul R Harris; Alejandro Venegas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  In silico experiment with an-antigen-toll like receptor-5 agonist fusion construct for immunogenic application to Helicobacter pylori.

Authors:  Mohamad Ali Haghighi; Ashraf Mohabati Mobarez; Ali Hatef Salmanian; Mohamad Moazeni; Mohamad Reza Zali; Mehdi Sadeghi; Jafar Amani
Journal:  Indian J Hum Genet       Date:  2013-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.